stoxline Quote Chart Rank Option Currency Glossary
ChemoCentryx, Inc. (CCXI)
51.99  0 (0%)    10-19 16:00
Open: 51.98
High: 51.98
Volume: 656,224
Pre. Close: 51.94
Low: 51.93
Market Cap: 0(M)
Technical analysis
2022-11-18 4:19:21 PM
Short term     
Mid term     
Targets 6-month :  60.73 1-year :  70.93
Resists First :  52 Second :  60.73
Pivot price 51.99
Supports First :  51.95 Second :  51.93
MAs MA(5) :  51.99 MA(20) :  51.99
MA(100) :  44.6 MA(250) :  33.93
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  50 D(3) :  50
RSI RSI(14): 79.1
52-week High :  52 Low :  14.94
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CCXI ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 52.05 - 52.3 52.3 - 52.52
Low: 51.36 - 51.66 51.66 - 51.92
Close: 51.55 - 52.01 52.01 - 52.4
Company Description

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.

Headline News

Sat, 15 Jun 2024
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights -

Thu, 20 Oct 2022

Thu, 01 Sep 2022
How Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger - The Business Journals

Thu, 04 Aug 2022
ChemoCentryx Stock More Than Doubles On $4B Buyout - Yahoo Finance

Tue, 01 Mar 2022
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights - GlobeNewswire

Mon, 27 Dec 2021
ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 70 (M)
Shares Float 59 (M)
Held by Insiders 12 (%)
Held by Institutions 79.7 (%)
Shares Short 6,560 (K)
Shares Short P.Month 5,640 (K)
Stock Financials
EPS -0.94
EPS Est Next Qtrly -0.32
EPS Est This Year -0.9
EPS Est Next Year -1.37
Book Value (p.s.) 5.17
Profit Margin 0 %
Operating Margin -508 %
Return on Assets (ttm) -18.5 %
Return on Equity (ttm) -45.4 %
Qtrly Rev. Growth -47.3 %
Gross Profit (p.s.) -0.73
Sales Per Share 0.39
EBITDA (p.s.) -1.93
Qtrly Earnings Growth 0 %
Operating Cash Flow -45 (M)
Levered Free Cash Flow -55 (M)
Stock Valuations
PE Ratio -55.31
PEG Ratio 0
Price to Book value 10.03
Price to Sales 133.21
Price to Cash Flow -80.52
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android